News | August 06, 2024
Lupin receives USFDA approval for Prednisolone Acetate Ophthalmic Suspension USP
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation
According to IQVIATM sales data for the 12-month period ending March 2024, the Combigan Ophthalmic Solution, 0.2%|0.5% market achieved annual sales of approximately $290.0 million
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
India confronts alarming rates of eye disorders, propelling the urgency of eyecare awareness
The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
Subscribe To Our Newsletter & Stay Updated
